{"id":52195,"date":"2025-12-29T20:38:04","date_gmt":"2025-12-29T12:38:04","guid":{"rendered":"https:\/\/flcube.com\/?p=52195"},"modified":"2025-12-29T20:38:05","modified_gmt":"2025-12-29T12:38:05","slug":"boan-biotech-ships-first-batch-of-boyoujing-aflibercept-biosimilar-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52195","title":{"rendered":"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China"},"content":{"rendered":"\n<p><strong>Shandong Boan Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6955:HKG\">HKG: 6955<\/a>) announced that the <strong>first commercial batch<\/strong> of its <strong>Aflibercept Intravitreal Injection (Boyoujing)<\/strong> has been officially shipped in Mainland China. The product, a <strong>biosimilar to Bayer\u2019s EYLEA<\/strong>, will be co\u2011commercialized by <strong>Boan Biotech<\/strong> and <strong>Ocumension Therapeutics<\/strong> (HKG: 1777) following <strong>NMPA approval in November\u202f2025<\/strong> for <strong>neovascular (wet) age\u2011related macular degeneration (nAMD)<\/strong> and <strong>diabetic macular edema (DME)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-regulatory-summary\">Product &amp; Regulatory Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Boyoujing (Aflibercept Intravitreal Injection)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shandong Boan Biotechnology (6955.HK)<\/td><\/tr><tr><td><strong>Commercial Partner<\/strong><\/td><td>Ocumension Therapeutics (1777.HK)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA approved (Nov\u202f2025)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>nAMD and DME in adults<\/td><\/tr><tr><td><strong>Reference Drug<\/strong><\/td><td>EYLEA (Bayer)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Humanized fusion protein; multi\u2011target VEGF inhibition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-disease-burden\">Market Opportunity &amp; Disease Burden<\/h2>\n\n\n\n<p><strong>China Retinal Disease Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>nAMD Prevalence<\/strong>: ~3.5\u202fmillion patients (2025); diagnosed rate &lt;20%<\/li>\n\n\n\n<li><strong>DME Prevalence<\/strong>: ~5.2\u202fmillion diabetic patients at risk; ~800,000 with clinically significant DME<\/li>\n\n\n\n<li><strong>Anti\u2011VEGF Market Size<\/strong>: <strong>\u00a512\u202fbillion<\/strong> (\u2248\u202fUS$1.7\u202fbillion) in 2025, growing at <strong>18% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Biosimilar Penetration<\/strong>: Expected to reach <strong>35\u201140%<\/strong> by 2028 under National Reimbursement Drug List (NRDL) pressure<\/li>\n<\/ul>\n\n\n\n<p><strong>Treatment Gap<\/strong>: Only <strong>15\u201120%<\/strong> of eligible nAMD\/DME patients receive anti\u2011VEGF therapy due to <strong>high cost<\/strong> (\u00a540,000\u201150,000\/year) and <strong>injection burden<\/strong> (monthly\/quarterly clinic visits).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Status<\/th><th>Price (\u00a5\/dose)<\/th><th>NRDL Status<\/th><\/tr><\/thead><tbody><tr><td><strong>EYLEA<\/strong><\/td><td>Bayer<\/td><td>Originators<\/td><td>\u00a55,888<\/td><td>Reimbursed (2023)<\/td><\/tr><tr><td><strong>Lucentis<\/strong><\/td><td>Roche\/Novartis<\/td><td>Originators<\/td><td>\u00a57,200<\/td><td>Reimbursed (2022)<\/td><\/tr><tr><td><strong>Beovu<\/strong><\/td><td>Novartis<\/td><td>Originators<\/td><td>\u00a55,400<\/td><td>Under review<\/td><\/tr><tr><td><strong>Boyoujing<\/strong><\/td><td><strong>Boan Biotech<\/strong><\/td><td>Biosimilar<\/td><td><strong>\u00a53,800\u20114,200<\/strong> (projected)<\/td><td><strong>Pending 2026 NRDL<\/strong><\/td><\/tr><tr><td><strong>OT\u2011702<\/strong><\/td><td>Ocumension<\/td><td>Biosimilar (partner)<\/td><td><strong>\u00a53,800\u20114,200<\/strong> (projected)<\/td><td><strong>Pending 2026 NRDL<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Biosimilar Wave<\/strong>: <strong>4\u20115 aflibercept biosimilars<\/strong> in late\u2011stage development; Boyoujing is <strong>second\u2011to\u2011market<\/strong> after <strong>Qilu Pharmaceutical\u2019s<\/strong> candidate (approved Sep\u202f2025). First\u2011mover advantage critical for NRDL inclusion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy-amp-financial-outlook\">Commercial Strategy &amp; Financial Outlook<\/h2>\n\n\n\n<p><strong>Co\u2011Commercialization Model<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Boan Biotech<\/strong>: Manufacturing, regulatory affairs, supply chain<\/li>\n\n\n\n<li><strong>Ocumension Therapeutics<\/strong>: Commercialization, physician outreach, hospital access<\/li>\n\n\n\n<li><strong>Revenue Split<\/strong>: <strong>60\/40<\/strong> (Boan\/Ocumension) based on industry benchmarks<\/li>\n<\/ul>\n\n\n\n<p><strong>Launch Timeline &amp; Projections<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Date<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>First shipment<\/strong><\/td><td>Dec\u202f2025<\/td><td>Initial batch to top 50 tertiary hospitals<\/td><\/tr><tr><td><strong>Full commercial launch<\/strong><\/td><td>Q1\u202f2026<\/td><td>National distribution via 300+ distributors<\/td><\/tr><tr><td><strong>NRDL submission<\/strong><\/td><td>Q2\u202f2026<\/td><td>Target 50% price reduction vs. EYLEA<\/td><\/tr><tr><td><strong>NRDL decision<\/strong><\/td><td>Dec\u202f2026<\/td><td>If approved, volume surge expected<\/td><\/tr><tr><td><strong>2026 sales forecast<\/strong><\/td><td>\u2013<\/td><td>\u00a5180\u2011220\u202fmillion (US$25\u201131\u202fmillion)<\/td><\/tr><tr><td><strong>2028 peak sales<\/strong><\/td><td>\u2013<\/td><td>\u00a51.2\u20111.5\u202fbillion (US$170\u2011210\u202fmillion)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Manufacturing<\/strong>: Boan\u2019s Weihai facility has <strong>2\u202fmillion doses\/year<\/strong> capacity, scalable to <strong>5\u202fmillion<\/strong> by 2027; current utilization <strong>15%<\/strong> for Boyoujing ramp\u2011up.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-differentiation-amp-clinical-profile\">Differentiation &amp; Clinical Profile<\/h2>\n\n\n\n<p><strong>Bioequivalence<\/strong>: Demonstrated <strong>pharmacokinetic (PK) equivalence<\/strong> and <strong>comparable safety<\/strong> to reference EYLEA in Phase\u202f1 studies; <strong>Phase\u202f3 bridging study<\/strong> (n=300) met primary endpoint of <strong>equivalent visual acuity improvement<\/strong> at Week\u202f52.<\/p>\n\n\n\n<p><strong>Clinical Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Longer\u2011lasting VEGF inhibition<\/strong>: Aflibercept\u2019s high affinity reduces injection frequency to <strong>q8\u201112 weeks<\/strong> after loading dose<\/li>\n\n\n\n<li><strong>Multi\u2011target blockade<\/strong>: Inhibits <strong>VEGF\u2011A, VEGF\u2011B, and PlGF<\/strong> vs. single\u2011target ranibizumab<\/li>\n\n\n\n<li><strong>Cost\u2011effectiveness<\/strong>: Projected <strong>annual savings of \u00a515,000\u201120,000<\/strong> per patient vs. originators<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements concerning Boyoujing\u2019s market penetration, NRDL inclusion timeline, revenue forecasts, and competitive positioning. Actual results may differ due to pricing negotiations, biosimilar competition, and market access dynamics..<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52196,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,220,4521,1024,40,156,44],"class_list":["post-52195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biosimilars","tag-boan-biotechnology","tag-hkg-1777","tag-hkg-6955","tag-market-launch","tag-ocumension-therapeutics","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its Aflibercept Intravitreal Injection (Boyoujing) has been officially shipped in Mainland China. The product, a biosimilar to Bayer\u2019s EYLEA, will be co\u2011commercialized by Boan Biotech and Ocumension Therapeutics (HKG: 1777) following NMPA approval in November\u202f2025 for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52195\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China\" \/>\n<meta property=\"og:description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its Aflibercept Intravitreal Injection (Boyoujing) has been officially shipped in Mainland China. The product, a biosimilar to Bayer\u2019s EYLEA, will be co\u2011commercialized by Boan Biotech and Ocumension Therapeutics (HKG: 1777) following NMPA approval in November\u202f2025 for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52195\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T12:38:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-29T12:38:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2904-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China\",\"datePublished\":\"2025-12-29T12:38:04+00:00\",\"dateModified\":\"2025-12-29T12:38:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2904-1.webp\",\"keywords\":[\"Biosimilars\",\"Boan Biotechnology\",\"HKG: 1777\",\"HKG: 6955\",\"Market launch\",\"Ocumension Therapeutics\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52195#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52195\",\"name\":\"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2904-1.webp\",\"datePublished\":\"2025-12-29T12:38:04+00:00\",\"dateModified\":\"2025-12-29T12:38:05+00:00\",\"description\":\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its Aflibercept Intravitreal Injection (Boyoujing) has been officially shipped in Mainland China. The product, a biosimilar to Bayer\u2019s EYLEA, will be co\u2011commercialized by Boan Biotech and Ocumension Therapeutics (HKG: 1777) following NMPA approval in November\u202f2025 for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52195\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2904-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2904-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52195#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its Aflibercept Intravitreal Injection (Boyoujing) has been officially shipped in Mainland China. The product, a biosimilar to Bayer\u2019s EYLEA, will be co\u2011commercialized by Boan Biotech and Ocumension Therapeutics (HKG: 1777) following NMPA approval in November\u202f2025 for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52195","og_locale":"en_US","og_type":"article","og_title":"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China","og_description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its Aflibercept Intravitreal Injection (Boyoujing) has been officially shipped in Mainland China. The product, a biosimilar to Bayer\u2019s EYLEA, will be co\u2011commercialized by Boan Biotech and Ocumension Therapeutics (HKG: 1777) following NMPA approval in November\u202f2025 for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME).","og_url":"https:\/\/flcube.com\/?p=52195","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T12:38:04+00:00","article_modified_time":"2025-12-29T12:38:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2904-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52195#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52195"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China","datePublished":"2025-12-29T12:38:04+00:00","dateModified":"2025-12-29T12:38:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52195"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52195#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2904-1.webp","keywords":["Biosimilars","Boan Biotechnology","HKG: 1777","HKG: 6955","Market launch","Ocumension Therapeutics","Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52195#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52195","url":"https:\/\/flcube.com\/?p=52195","name":"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52195#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52195#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2904-1.webp","datePublished":"2025-12-29T12:38:04+00:00","dateModified":"2025-12-29T12:38:05+00:00","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its Aflibercept Intravitreal Injection (Boyoujing) has been officially shipped in Mainland China. The product, a biosimilar to Bayer\u2019s EYLEA, will be co\u2011commercialized by Boan Biotech and Ocumension Therapeutics (HKG: 1777) following NMPA approval in November\u202f2025 for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52195#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52195"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52195#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2904-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2904-1.webp","width":1080,"height":608,"caption":"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52195#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2904-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52195"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52195\/revisions"}],"predecessor-version":[{"id":52197,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52195\/revisions\/52197"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52196"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}